Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 158 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infliximab Clear all
Recruiting Phase 2 Interventional

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

NCT06136546
View directory record Official record
Conditions
Depressive Disorder, Major, Inflammation
Interventions
Infliximab, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 17, 2026, 12:18 AM EDT
Active, not recruiting Phase 4 Interventional

Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial

NCT04835506
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Infliximab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
16 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 12:18 AM EDT
Completed No phase listed Observational Results available

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
no intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
34
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 17, 2026, 12:18 AM EDT
Not listed No phase listed Observational

Infliximab Proactive Drug Monitoring in the Pediatric IBD Population

NCT04921670
View directory record Official record
Conditions
Inflammatory Bone Disease
Interventions
Infliximab Assay
Diagnostic Test
Lead sponsor
Cares, Kristen, M.D.
Other
Eligibility
5 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 4 Interventional Results available

RESTART C0168Z05 Rheumatoid Arthritis Study

NCT00714493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab
Biological
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 17, 2026, 12:18 AM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 12:18 AM EDT
Terminated Phase 4 Interventional Results available

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

NCT02353780
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab
Drug
Lead sponsor
Dr. Larry W. Moreland
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 2 Interventional Results available

Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C

NCT00512278
View directory record Official record
Conditions
Hepatitis C
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Nizar Zein
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Port Orange, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 17, 2026, 12:18 AM EDT
Recruiting Phase 2 Interventional

Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis

NCT06941376
View directory record Official record
Conditions
Relapsing Polychondritis
Interventions
Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 3 Interventional Results available

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

NCT04505410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
Other · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 17, 2026, 12:18 AM EDT
Terminated Phase 2 Interventional Results available

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

NCT04438382
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
Interventions
Infliximab, Intravenous Immunoglobulin Therapy, Prednisone, Methylprednisolone
Biological · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
Chicago, Illinois • Baltimore, Maryland • Battle Creek, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 3 Interventional Results available

CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)

NCT03945019
View directory record Official record
Conditions
Crohn's Disease
Interventions
CT-P13 SC (Infliximab), Placebo SC
Biological · Other
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 75 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease

NCT00487396
View directory record Official record
Conditions
Crohn's Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
10 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 17, 2026, 12:18 AM EDT
Not listed No phase listed Observational

Use of Immunosuppressive Therapy for Sarcoidosis

NCT02356445
View directory record Official record
Conditions
Sarcoidosis
Interventions
Cytotoxic drug
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 90 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 1 Interventional

Protein and Energy Metabolism in Pediatric Crohn's Disease

NCT00583232
View directory record Official record
Conditions
Crohn's Disease, Protein Metabolism, Energy Metabolism
Interventions
Stable isotope infusions
Drug
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 17, 2026, 12:18 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 12:18 AM EDT
Withdrawn Phase 2 Interventional

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

NCT06646016
View directory record Official record
Conditions
Immune-related Colitis
Interventions
Methoxsalen, Infliximab, Vedolizumab
Drug
Lead sponsor
Therakos LLC
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 17, 2026, 12:18 AM EDT
Not listed No phase listed Observational

Registry for Advanced Sarcodiosis

NCT03769987
View directory record Official record
Conditions
Sarcoidosis
Interventions
observation
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
15 Years to 100 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 3 Interventional Results available

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

NCT01004432
View directory record Official record
Conditions
Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions
Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV
Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
89
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 17, 2026, 12:18 AM EDT
Terminated Not applicable Interventional

Metabolic Response to Infliximab in Pediatric Ulcerative Colitis

NCT00586807
View directory record Official record
Conditions
Ulcerative Colitis, Protein Metabolism, Energy Expenditure
Interventions
Stable amino acid isotopes
Other
Lead sponsor
Indiana University
Other
Eligibility
6 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2009 · Synced Oct 17, 2026, 12:18 AM EDT
Completed No phase listed Observational

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

NCT02728934
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Golimumab Intravenous (IV), Infliximab, Biosimilar Infliximab
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
85
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

NCT00094458
View directory record Official record
Conditions
Crohn Disease
Interventions
infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Biological · Other · Drug
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
21 Years to 99 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 17, 2026, 12:18 AM EDT
Completed Phase 3 Interventional

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

NCT00338650
View directory record Official record
Conditions
Crohn's Disease
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 17, 2026, 12:18 AM EDT